Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 8
Submit an article Journal homepage
40
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study

Michael Crump Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Room 5-108, Toronto M5G 2M9, Canada
,
Stephen Couban Department of Hematology, Queen Elizabeth II, Health Sciences Centre, Halifax, Canada
,
Ralph Meyer Hamilton Health Science Corporation-Henderson Site, Hamilton, Canada
,
Leona Rudinskas Department of Medical Oncology, Humber River Regional Hospital--Church Site, Toronto, Canada
,
Brent Zanke Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Room 5-108, Toronto M5G 2M9, Canada
,
Stefan Gluck Department of Medicine, Tom Baker Cancer Centre, Calgary, Canada
,
Andrew Maksymiuk Section of Medical Oncology, Saskatoon Cancer Centre, Saskatoon, Canada
,
Paul Hoskins Department of Medical Oncology, BC Cancer Agency--Vancouver CC, Vancouver, Canada
,
Sarah Matthews National Cancer Institute of Canada--Clinical Trials Group, Kingston, Canada
&
Elizabeth Eisenhauer National Cancer Institute of Canada--Clinical Trials Group, Kingston, Canada
 show all
Pages 1581-1587 | Published online: 01 Jul 2009

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mark Kirschbaum. (2009) Comeback for the camptothecins?. Leukemia & Lymphoma 50:12, pages 1914-1915.
Read now
Sonali M. Smith, Jeffrey L. Johnson, Donna Niedzwiecki, J. Paul Eder, George Canellos, Bruce D. Cheson, Nancy L. Bartlett & for the Cancer and Leukemia Group B. (2006) Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906. Leukemia & Lymphoma 47:8, pages 1511-1517.
Read now

Articles from other publishers (14)

YaJuan Shao, Mei Guan, ShuChang Chen, Ning Jia & YuZhou Wang. (2014) Topotecan combined with Ifosfamide, Etoposide, and l-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma. Medical Oncology 32:1.
Crossref
K A Kasow, C F Stewart, R C Barfield, N L Wright, C Li, D K Srivastava, W Leung, E M Horwitz, L C Bowman, R Handgretinger & G A Hale. (2012) A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up. Bone Marrow Transplantation 47:11, pages 1448-1454.
Crossref
Nancy L. Bartlett, Jeffrey L. Johnson, Nina Wagner-Johnston, Mark J. Ratain & Bruce A. Peterson. (2008) Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemotherapy and Pharmacology 63:5, pages 793-798.
Crossref
Carsten Zwick, Josef Birkmann, Norma Peter, Heinrich Bodenstein, Roland Fuchs, Mathias Hänel, Marcel Reiser, Manfred Hensel, Michael Clemens, Samira Zeynalova, Marita Ziepert & Michael Pfreundschuh. (2008) Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Annals of Hematology 87:9, pages 717-726.
Crossref
Louisa J. Lewis, Prakash Mistry, Peter A. Charlton, Hilary Thomas & Helen M. Coley. (2007) Mode of action of the novel phenazine anticancer agents XR11576 and XR5944. Anti-Cancer Drugs 18:2, pages 139-148.
Crossref
F. Hartmann, R. Schmits & M. Pfreundschuh. 2007. Therapiekonzepte Onkologie. Therapiekonzepte Onkologie 385 420 .
George R. Simon, Richard M. Lush, Jana Gump, Leticia Tetteh, Charles Williams, Alan Cantor, Scott Antonia, Christopher Garrett, Caio Rocha-Lima, Mayer Fishman, Daniel M. Sullivan & Pamela N. Munster. (2006) Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Molecular Cancer Therapeutics 5:8, pages 2130-2137.
Crossref
Peter G. Rose, Maurie Markman, Jeffrey G. Bell & Nancy L. Fusco. (2006) Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: A phase I Gynecologic Oncology Group study. Gynecologic Oncology 102:2, pages 236-239.
Crossref
Jennifer Garst, Richard Buller, Stephen Lane & Jeffrey Crawford. (2005) Topotecan in the Treatment of Elderly Patients with Relapsed Small-Cell Lung Cancer. Clinical Lung Cancer 7:3, pages 190-196.
Crossref
N C Levitt, D J Propper, S Madhusudan, J P Braybrooke, C Echeta, R te Poele, S L Davies, E Flanagan, I D Hickson, S Joel & T S Ganesan. (2005) Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. British Journal of Cancer 93:1, pages 60-69.
Crossref
Max Kreditor, Matthew Fink & Howard S. Hochster. 2005. 61 100 .
Hans Gelderblom & Alex Sparreboom. 2005. Drugs Affecting Growth of Tumours. Drugs Affecting Growth of Tumours 83 100 .
Miklos Pless, Karim Belhadj, Hans D. Menssen, Wolfgang Kern, Bertrand Coiffier, Jürgen Wolf, Richard Herrmann, Eckhard Thiel, Doug Bootle, Ivo Sklenar, Christian Müller, Les Choi, Carl Porter & Renaud Capdeville. (2004) Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma. Clinical Cancer Research 10:4, pages 1299-1305.
Crossref
. (2003) Current Awareness in Hematological Oncology. Hematological Oncology 21:1, pages 43-50.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.